FCN-289

N/A

Report date: 2025/03/31 10:53:02
NME

Base Information

Drug NameFCN-289
Drug Alias NameFCN-289
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFochon Pharmaceuticals Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFochon Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A